A Clinical Study of Vonoprazan Fumarate Tablets for the Treatment of Non-erosive Reflux Disease
-
摘要:
目的 研究富马酸伏诺拉生片与艾司奥美拉唑镁肠溶片在治疗非糜烂性反流病(non-erosive reflux disease,NERD)中的效果及不良反应对比。 方法 选取124例NERD患者,采用随机数字表法分为观察组62例和对照组62例。观察组给予富马酸伏诺拉生片,对照组给予艾司奥美拉唑镁肠溶片,疗程均为4周。对幽门螺旋杆菌(helicobacter pylori,HP)阳性的患者进一步根除HP。比较2组患者的临床疗效、反流性疾病问卷量表(reflux disease questionnaire,RDQ)评分、匹兹堡睡眠质量指数(pittsburgh sleep quality index,PSQI) 评分、治疗前后食管pH值变化、HP根除率及不良反应发生率。 结果 观察组总有效率高于对照组(P < 0.05),观察组治疗后RDQ评分低于对照组(P < 0.05),观察组治疗后PSQI评分低于对照组(P < 0.05),观察组治疗后pH < 4反流次数、> 5 min反流次数和pH < 4总时间低于对照组(P < 0.05),观察组HP根除率高于对照组(P < 0.05)。观察组和对照组比较,总不良反应率无明显差异(P > 0.05)。 结论 在治疗非糜烂性反流病方面,富马酸伏诺拉生片与艾司奥美拉唑镁肠溶片对比,疗效显著,可改善睡眠质量,抑酸更强,提高HP根除率,并不增加不良反应。 -
关键词:
- 富马酸伏诺拉生片 /
- 艾司奥美拉唑镁肠溶片 /
- 非糜烂性反流病
Abstract:Objective To study the efficacy and adverse reactions of vonoprazan fumarate tablets and esomeprazole magnesium enteric-coated tablets in the treatment of non-erosive reflux disease(NERD). Methods A total of 124 patients with NERD were selected and divided into treatment group(62 cases) and control group(62 cases) by random number table method. Treatment group received vohoprazan fumarate tablet, while control group received esomeprazole magnesium enteric-coated tablet, and the course of treatment was 4 weeks. HP was eradicated in helicobacter pylori(HP)-positive patients. The clinical efficacy, reflux disease questionnaire(RDQ )score, pittsburgh sleep quality index score, changes of esophageal pH before and after treatment、HP eradication rate and incidence of adverse reactions were compared between the two groups. Results The treatment group showed a higher overall effectiveness compared to the control group(P < 0.05). After treatment, the RDQ scores in the treatment group were lower than those in the control group(P < 0.05). Similarly, the PSQI scores in the treatment group were lower than those in the control group(P < 0.05). Additionally, the treatment group exhibited fewer reflux episodes with pH < 4, reflux episodes lasting > 5 minutes, and a lower total time with pH < 4 compared to the control group(P < 0.05). The eradication rate of HP in the treatment group was higher than that in the control group(P < 0.05). There was no significant difference in the overall rate of adverse reactions between the treatment group and the control group(P > 0.05). Conclusion In the treatment of non-erosive reflux disease, compared to esomeprazole magnesium enteric-coated tablets, vonoprazan fumarate tablets show significant efficacy, improve sleep quality, provide stronger acid suppression, increase the eradication rate of Helicobacter pylori(HP), and do not increase adverse reactions. -
表 1 观察组和对照组一般资料比较[$\bar x \pm s$/n(%)]
Table 1. Comparison of general data between treatment group and control group[$ \bar x \pm s $/n(%)]
组别 性别
(男/女)年龄
(岁)BMI
(kg/m2)吸烟 饮酒 HP感染 观察组 27/35 57.74±12.81 23.86±2.58 10(16.13) 12(19.35) 34(54.84) 对照组 24/38 56.79±11.29 23.12±2.27 9(14.52) 13(20.97) 32(51.61) t/χ2 0.300 0.439 1.689 0.062 0.050 0.130 P 0.584 0.662 0.094 0.803 0.823 0.719 表 2 2组患者治疗后临床疗效[n(%)]
Table 2. Clinical efficacy of two groups of patients after treatment [n(%)]
组别 n 显效 有效 无效 总有效率 观察组 62 34(54.84) 24(38.71) 4(6.45) 58(93.55) 对照组 62 29(46.77) 18(29.03) 15(24.19) 47(75.81) χ2 / / / / 7.521 P / / / / 0.006* *P < 0.05。 表 3 2组患者治疗前后RDQ评分[($\bar x \pm s$),分]
Table 3. RDQ scores before and after treatment in the two groups [($\bar x \pm s$),points]
组别 n 治疗前 治疗后 观察组 62 17.13±6.11 9.03±3.28 对照组 62 16.81±5.59 10.48±2.86 t / 0.307 −2.624 P / 0.760 0.010* *P < 0.05。 表 4 2组患者治疗前后PSQI评分[($\bar x \pm s$),分]
Table 4. PSQI score before and after treatment in the two groups [($\bar x \pm s$),points]
组别 n 治疗前 治疗后 观察组 62 7.90±2.51 4.76±1.89 对照组 62 7.85±1.57 5.95±1.74 t / 0.129 −3.660 P / 0.898 < 0.001* *P < 0.05。 表 5 2组患者治疗前后食管pH检测变化($\bar x \pm s$)
Table 5. The changes of esophageal pH before and after treatment in the two groups of patients($\bar x \pm s$)
组别 n pH < 4反流次数(次) > 5 min反流次数(次) pH < 4总时间(min) 治疗前 治疗后 治疗前 治疗后 治疗前 治疗后 观察组 62 28.37±8.71 11.16±2.57 5.76±2.41 1.69±0.86 74.84±12.30 16.81±5.02 对照组 62 28.05±8.15 13.02±5.36 5.42±2.27 2.87±1.15 71.77±11.23 23.97±6.17 t / −0.213 2.457 0.804 −6.447 1.449 −7.115 P / 0.832 0.015 0.423 < 0.001* 0.150 < 0.001* *P < 0.05。 表 6 2组患者HP感染者根除率(%)
Table 6. The eradication rate of HP infection in the two groups of patients (%)
组别 n 根除率(%) 根除前HP阳性 根除后HP阴性 观察组 34 31 31/34(91.2) 对照组 32 20 20/32(62.5) χ2 / / 4.030 P / / 0.045* *P < 0.05。 -
[1] Savarino V,Antonioli L,Fornai M,et al. An update of pharmacology,efficacy,and safety of vonoprazan in acid-related disorders[J]. Expert Rev Gastroenterol Hepatol,2022,16(5):401-410. doi: 10.1080/17474124.2021.1984878 [2] 沈芸,陶雯佳,杨勤. 新型钾离子竞争性酸阻滞剂在治疗酸相关疾病中的研究进展[J]. 中国中西医结合消化杂志,2020,28(10):811-814. [3] 中华医学会消化病学分会. 2020年中国胃食管反流病专家共识意见[J]. 中华消化杂志,2020,40(10):649-663. [4] 崔亚,姜礼双,卜平. 反流性食管炎与非糜烂性胃食管反流病临床特征比较[J]. 中国医师杂志,2018,20(8):1151-1154. [5] 杜秀云,赛米·赛麦提,赵新胜,等. P物质和降钙素基因相关肽及炎症因子在非糜烂性食管炎发生中的作用研究[J]. 中华胃食管反流病电子杂志,2020,7(3):158-163. [6] 中华中医药学会脾胃病分会. 胃食管反流病中医诊疗专家共识意见(2017)[J]. 中国中西医结合消化杂志,2017,25(5):321-326. [7] Kim M,Yu H Y,Ju H,et al. Induction of detrusor underactivity by extensive vascular endothelial damages of iliac arteries in a rat model and its pathophysiology in the genetic levels[J]. Sci Rep,2019,9(1):16328. doi: 10.1038/s41598-019-52811-4 [8] Maret-Ouda J,Markar S R,Lagergren J. Gastroesophageal reflux disease: A review[J]. JAMA,2020,324(24):2536-2547. doi: 10.1001/jama.2020.21360 [9] Lim K G,Morgenthaler T I,Katzka D A. Sleep and nocturnal gastroesophageal reflux: An update[J]. Chest,2018,154(4):963-971. doi: 10.1016/j.chest.2018.05.030 [10] Park Chan Hyuk. Treatment of non-erosive reflux disease and dynamics of the esophageal microbiome: A prospective multic-enter study[J]. Scientific Reports,2020,10(1):1025. doi: 10.1038/s41598-020-57894-y [11] Echizen H. The first-in-class potassium-competitive acid blocker,Vonoprazan Fumarate: Pharmacokinetic and pharmacodynamic considerations[J]. Clin Pharmacokinet,2016,55(4):409-418. doi: 10.1007/s40262-015-0326-7 [12] Okanobu H,Kohno T,Mouri R,et al. Efficacy of vonoprazan 10 mg compared with 20 mg for the initial treatment in patients with erosive esophagitis: A randomized pilot study[J]. Esophagus,2021,18(3):669-675. doi: 10.1007/s10388-020-00798-7 [13] Cheng Y,Liu J,Tan X,et al. Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease: A systematic review and meta-analysis[J]. Dig Dis Sci,2021,66(1):19-28. doi: 10.1007/s10620-020-06141-5 [14] Akiyama J,Hosaka H,Kuribayashi S,et al. Efficacy of vonoprazan,a novel potassium-competitive acid blocker,in patients with proton pump inhibitor-refractory acid reflux[J]. Digestion,2020,101(2):174-183. doi: 10.1159/000497775 [15] Takenouchi N,Hoshino S,Hoshikawa Y,et al. Risk of hemorrhage and stricture significantly increases in elderly patients with proton pump inhibitor (PPI)-resistant reflux esophagitis[J]. Esophagus,2020,17(1):87-91. doi: 10.1007/s10388-019-00702-y [16] 黄博,崔德军,赵寻,等. 伏诺拉生治疗难治性反流性食管炎的临床疗效及安全性[J]. 临床合理用药杂志,2021,14(25):18-20. [17] Takeuchi T,Furuta T,Fujiwara Y,et al. Randomised trial of acid inhibition by vonoprazan 10/20mg once daily vs rabeprazole 10/20mg twice daily in healthy Japanese volunteers (SAMURAI pH study)[J]. Aliment Pharmacol Ther,2020,51(5):534-543. doi: 10.1111/apt.15641 [18] 赵莹,赵晶. 伊托必利联合富马酸伏诺拉生片治疗胃食管反流病的疗效及对患者CGRP、5-HT水平变化的影响[J]. 中国中西医结合消化杂志,2022,30(1):16-20. [19] 张泽丹,黄敏,谭平. 不同亚型胃食管反流病睡眠障碍状况及治疗对睡眠障碍的影响[J]. 中华保健医学杂志,2021,23(2):120-122. [20] 里提甫江·买买提艾力,买买提·依斯热依力,阿巴伯克力·乌斯曼,等. 焦虑、抑郁及睡眠障碍与胃食管反流病的相关研究[J]. 中华胃食管反流病电子杂志,2020,7(4):202-206. [21] Rokkas T,Gisbert JP,Malfertheiner P,et al. Comparative effectiveness of multiple different first-line treatment regimens for helicobacter pylori infection: A network meta-analysis[J]. Gastroenterology,2021,161(2):495-507. doi: 10.1053/j.gastro.2021.04.012 [22] Ford A C,Yuan Y,Forman D,et al. Helicobacter pylori eradication for the prevention of gastric neoplasia[J]. Cohrane Database of Systematic Reviews,2020,7(7):CD005583. [23] Kato M,Ota H,Okuda M,et al. Guidelines for the manage-ment of elicobacter pylori infection in Japan: 2016 revised edition[J]. Helicobacter,2019,24(4):e12597. doi: 10.1111/hel.12597 [24] Dong S Q,Singh T P,Wei X,et al. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for helicobacter pylori eradication therapy: Is superiority an illusion?[J]. Helicobacter,2017,22(6):e12438. doi: 10.1111/hel.12438